Moneycontrol PRO

Buy Aster DM Healthcare; target of Rs 270: ICICI Direct

ICICI Direct is bullish on Aster DM Healthcare has recommended buy rating on the stock with a target price of Rs 270 in its research report dated May 25, 2022.

May 30, 2022 / 03:55 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Aster DM Healthcare

Aster operates in segments like hospitals, clinics, retail pharmacies and provides healthcare services to patients across economic segments in several GCC states through various brands such as Aster, Medcare and Access. Its network consists of 13 hospitals, 109 clinics and 240 retail pharmacies in GCC states;14 hospitals, 11 clinics, 131 pharmacies and 114 labs in India; total bed capacity: GCC: 1160, India: 3905 • Revenue break-up FY22: hospitals: 56%, pharmacies: 21%, clinics: 23% with GCC & India contributing 77% & 23% of revenues, respectively.


Maintain BUY for a unique blend of GCC healthcare network and a quest to expand in India with a calibrated capex approach. We value Aster DM at an SOTP of Rs 270.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 30, 2022 03:55 pm
ISO 27001 - BSI Assurance Mark